SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

11 Oct 2016 07:00

RNS Number : 1617M
Victrex PLC
11 October 2016
 
 

 

 

 

11 October 2016

Victrex plc: Full year and pre-close trading update

'Improved second half; good finish to 2016'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its full year and pre-close trading update for the financial year ended 30 September 2016, ahead of its preliminary results on 6 December 2016.

In line with expectations, Victrex delivered an improved performance in the second half and a good finish to 2016.

The core business was in growth, with Aerospace and Automotive performing well, and a more stable performance in Oil & Gas during the second half. Sales volumes for the large Consumer Electronics business were delivered on plan during Q4, with overall second half volumes more than double those in the first half. Q4, overall, saw a good performance with Group revenue up 8% to £73.7m (Q4 2015: £68.0m) and Q4 Group sales volume up 9% to 1,216 tonnes (Q4 2015: 1,119 tonnes).

Despite a positive finish to 2016, full year Group revenue declined by 4% to £252.3m (FY2015: £263.5m), reflecting the year on year fall in Consumer Electronics volumes, which were more than 30% down. Full year Group sales volume was down 6% at 3,952 tonnes (FY 2015: 4,217 tonnes).

Medical revenue (Invibio) for the full year of £50.8m (FY 2015: £50.5m) reflects a stable Spine market in the US. Growth outside of the US, in emerging markets, remains positive.

Our mega-programmes continue to make progress, with the Magma Oil & Gas project delivering first meaningful revenues of over £1m in FY16. Incremental investment opportunities aligned to our mega-programmes are also being progressed, which would further support delivery of the Group's downstream strategy and growth pipeline.

 

Outlook

 

As we start our new financial year, our core business remains robust. However, we remain mindful, as previously communicated, that our early planning assumption suggests Consumer Electronics volumes will be significantly lower in 2017, compared to 2016. This would also impact our operating leverage.

 

Whilst we will continue to invest in our 'front end' commercial, marketing and technical functions, to help drive adoption of our mega-programmes, we will also further enhance our ongoing focus on cost efficiency opportunities over the coming year.

 

With a differentiated strategy, a strong pipeline and a highly cash generative business model, Victrex remains in a good position to drive shareholder value for the medium to longer term.

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Teneo Blue Rubicon:

Charles Armitstead +44 (0) 207 260 2700

 

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the Automotive, Aerospace, Energy, Electronics and Medical markets. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we deliver leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGGGBUUUPQGQU
Date   Source Headline
30th Nov 20161:30 pmRNSTotal Voting Rights
17th Nov 20162:19 pmRNSDirector/PDMR Shareholding
10th Nov 201611:11 amRNSAdditional Listing
31st Oct 20162:39 pmRNSTotal Voting Rights
18th Oct 20162:10 pmRNSDirector/PDMR Shareholding
11th Oct 20167:00 amRNSTrading Statement
30th Sep 20161:11 pmRNSTotal Voting Rights
19th Sep 20164:28 pmRNSDirector/PDMR Shareholding
19th Sep 20163:18 pmRNSHolding(s) in Company
31st Aug 20169:28 amRNSTotal Voting Rights
17th Aug 20163:46 pmRNSDirector/PDMR Shareholding
29th Jul 20162:47 pmRNSTotal Voting Rights
28th Jul 20162:57 pmRNSHolding(s) in Company
26th Jul 20167:00 amRNSInterim Management Statement
19th Jul 20164:34 pmRNSDirector/PDMR Shareholding
30th Jun 201610:00 amRNSTotal Voting Rights
17th Jun 20163:56 pmRNSDirector/PDMR Shareholding
14th Jun 20164:42 pmRNSHolding(s) in Company
14th Jun 20164:24 pmRNSHolding(s) in Company
1st Jun 20169:02 amRNSBlock listing Interim Review
31st May 201611:42 amRNSTotal Voting Rights
26th May 20164:26 pmRNSHolding(s) in Company
17th May 20164:11 pmRNSDirector/PDMR Shareholding
16th May 20167:00 amRNSHalf-year Report
3rd May 20163:27 pmRNSHolding(s) in Company
3rd May 20163:15 pmRNSHolding(s) in Company
3rd May 20163:00 pmRNSHolding(s) in Company
29th Apr 201610:00 amRNSTotal Voting Rights
28th Apr 20167:00 amRNSResolution of US FTC inquiry
21st Apr 20167:00 amRNSDirector Declaration
19th Apr 201611:07 amRNSDirector/PDMR Shareholding
7th Apr 20167:00 amRNSTrading Statement
31st Mar 20162:51 pmRNSTotal Voting Rights
31st Mar 20161:45 pmRNSTotal Voting Rights
17th Mar 201610:15 amRNSDirector/PDMR Shareholding
1st Mar 20165:00 pmRNSDirector/PDMR Shareholding
29th Feb 20162:18 pmRNSTotal Voting Rights
26th Feb 20163:09 pmRNSHome Member State
17th Feb 201611:27 amRNSDirector/PDMR Shareholding
10th Feb 20163:55 pmRNSResult of AGM
10th Feb 20167:00 amRNSAGM Statement
9th Feb 20164:44 pmRNSHolding(s) in Company
5th Feb 20161:38 pmRNSGrant of Options
29th Jan 20169:27 amRNSTotal Voting Rights
19th Jan 201611:39 amRNSDirector/PDMR Shareholding
19th Jan 201610:08 amRNSDirector Declaration
5th Jan 201612:00 pmRNSAnnual Financial Report
31st Dec 201510:00 amRNSTotal Voting Rights
17th Dec 20154:23 pmRNSHolding(s) in Company
17th Dec 20153:36 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.